# A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

> **NCT03078478** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1609 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin degludec
- **DRUG:** Insulin glargine

## Key facts

- **NCT ID:** NCT03078478
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-13
- **Primary completion:** 2019-02-13
- **Final completion:** 2019-03-04
- **Target enrollment:** 1609 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03078478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03078478, "A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03078478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*